BioDelivery Sciences signs deal with nonprofit group

01/26/2009 | Pharmaceutical Business Review Online

BioDelivery Sciences International has agreed to work with the nonprofit Drugs for Neglected Diseases initiative in testing the safety and efficacy of Bioral Amphotericin B, a treatment for leishmaniasis, Chagas' disease and other communicable diseases. Bioral Amphotericin B uses BDSI's patented Bioral drug delivery technology to allow the drug to be administered orally rather than intravenously.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Director, Payer Marketing
Avalere Health
Washington, DC
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX